These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 25433956)
1. How to mechanistically explain the CONDOR study data. Spies CM; Stemmler E; Buttgereit F Med Hypotheses; 2015 Jan; 84(1):14-9. PubMed ID: 25433956 [TBL] [Abstract][Full Text] [Related]
2. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563 [TBL] [Abstract][Full Text] [Related]
3. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective. Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942 [TBL] [Abstract][Full Text] [Related]
4. Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR). Lanas A; Goldstein JL; Chan FK; Wilcox CM; Peura DA; Li C; Sands GH; Scheiman JM Aliment Pharmacol Ther; 2012 Sep; 36(5):485-92. PubMed ID: 22804104 [TBL] [Abstract][Full Text] [Related]
5. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands. Al MJ; Maniadakis N; Grijseels EW; Janssen M Value Health; 2008; 11(4):589-99. PubMed ID: 18194404 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial. Kellner HL; Li C; Essex MN Curr Med Res Opin; 2012 Sep; 28(9):1537-45. PubMed ID: 22852870 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. Sakamoto C; Soen S Digestion; 2011; 83(1-2):108-23. PubMed ID: 21042022 [TBL] [Abstract][Full Text] [Related]
8. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Geis GS J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538 [TBL] [Abstract][Full Text] [Related]
9. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Geis GS Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544 [TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial. Brereton N; Winn B; Akehurst R J Med Econ; 2012; 15(3):465-72. PubMed ID: 22260652 [TBL] [Abstract][Full Text] [Related]
11. The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group. Hasegawa M; Horiki N; Tanaka K; Wakabayashi H; Tano S; Katsurahara M; Uchida A; Takei Y; Sudo A Mod Rheumatol; 2013 Nov; 23(6):1172-8. PubMed ID: 23306427 [TBL] [Abstract][Full Text] [Related]
12. Aldosterone glucuronidation inhibition as a potential mechanism for arterial dysfunction associated with chronic celecoxib and diclofenac use in patients with rheumatoid arthritis. Crilly MA; Mangoni AA; Knights KM Clin Exp Rheumatol; 2013; 31(5):691-8. PubMed ID: 23899748 [TBL] [Abstract][Full Text] [Related]
13. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model. Brereton N; Pennington B; Ekelund M; Akehurst R J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585 [TBL] [Abstract][Full Text] [Related]
14. Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines. Zwolinska-Wcislo M; Krzysiek-Maczka G; Ptak-Belowska A; Karczewska E; Pajdo R; Sliwowski Z; Urbanczyk K; Drozdowicz D; Konturek SJ; Pawlik WW; Brzozowski T J Physiol Pharmacol; 2011 Jun; 62(3):357-68. PubMed ID: 21893697 [TBL] [Abstract][Full Text] [Related]
17. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Hochberg MC Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069 [TBL] [Abstract][Full Text] [Related]
18. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Maetzel A; Krahn M; Naglie G Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781 [TBL] [Abstract][Full Text] [Related]
19. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. Chan FK; Hung LC; Suen BY; Wu JC; Lee KC; Leung VK; Hui AJ; To KF; Leung WK; Wong VW; Chung SC; Sung JJ N Engl J Med; 2002 Dec; 347(26):2104-10. PubMed ID: 12501222 [TBL] [Abstract][Full Text] [Related]
20. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Zhao SZ; Wentworth C; Burke TA; Makuch RW Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]